Evaluation of the humoral response in patients receiving half doses of AstraZeneca and BNT162b2 vaccines in a heterogenous prime-boost schedule.
Not Applicable
- Conditions
- The humoral response to the half-doses of AstraZeneca and BNT162b2 vaccines in a heterogenous prime-boost schedule..T80.62Other serum reaction due to vaccination
- Registration Number
- IRCT20210801052044N1
- Lead Sponsor
- Invicta Research and Development Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Willingness to take part in the clinical trial
Age between 18 and 55 years old
Exclusion Criteria
Age above 55 years old
Diagnosed with diabetes, hypertension, heart disease, chronic pulmonarydiseases, severe allergies
Obesity as defined by BMI > 30
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anti-SARS-CoV-2 antibody level. Timepoint: On the day of dose-2 of the vaccine and 8-10 days later. Method of measurement: IVD Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics).
- Secondary Outcome Measures
Name Time Method